Oyster Point Pharma Inc. v. The Controller Of Patents And Designs Anr.

In the high-stakes world of pharmaceutical innovation, the difference between a breakthrough and a rejection can hinge on a single overlooked piece of evidence. When a patent examiner dismisses experimental data showing enhanced efficacy and stability, the question becomes: does the system allow innovators to correct that oversight? This case from July 2023 reveals exactly how critical it is for patent authorities to engage with the science behind a new drug form—and what happens when they don't.

Oyster Point Pharma Inc., a pharmaceutical company, found itself at a crossroads when the Assistant Controller of Patents and Designs rejected its patent application. The rejection was grounded in prior art references, invoking Sections 2(1)(ja) and 3(d) of the Patents Act, 1970—provisions that deal with novelty and the patentability of new forms of known substances. At the heart of Oyster Point's application was a mono-citrate salt, a specific salt form of a compound that the company believed offered meaningful therapeutic advantages. To support its position, Oyster Point had filed experimental data during the prosecution stage, aiming to demonstrate that this mono-citrate salt was not merely a minor variation but a genuinely improved form with enhanced efficacy and stability.

Oyster Point Pharma Inc. took its fight to the High Court, arguing that the Assistant Controller's rejection failed to grapple with the most important evidence in the case: the experimental data showing enhanced efficacy and stability of the mono-citrate salt. The appellant contended that under Section 3(d) of the Patents Act, a new form of a known substance can be patentable—but only when it demonstrates a meaningful therapeutic advantage. Oyster Point asserted that its experimental studies, filed during prosecution, provided exactly this kind of comparative proof. On the other side, the Controller stood by the rejection, having relied on prior art to conclude that the mono-citrate salt lacked the requisite novelty or improvement to warrant patent protection. The legal friction centered on a fundamental question: did the Controller properly weigh the appellant's evidence of enhanced efficacy and stability, or did the rejection rest on an incomplete assessment of the record?

The High Court sided with Oyster Point Pharma Inc., identifying a critical flaw in the Controller's decision-making process. The court found that the Controller had failed to consider the crucial experimental evidence regarding the efficacy and stability of the mono-citrate salt—evidence that Oyster Point had submitted during prosecution specifically to satisfy the requirements of patentability for a new form of a known substance. Rather than rendering a final judgment on the merits, the court remanded the case, sending it back for reconsideration with proper attention to the appellant's experimental data. This outcome underscored a vital principle: patent authorities cannot ignore comparative experimental studies when determining whether a new salt form demonstrates the enhanced efficacy required for patentability under the Act.

For founders and IP professionals in the pharmaceutical and life sciences space, this case delivers a clear and actionable lesson: when pursuing a patent for a new form of a known substance, comparative experimental data is not optional—it is essential. Filing robust studies that demonstrate enhanced efficacy and stability during prosecution can make the difference between approval and rejection. Equally important, if a rejection occurs, scrutinize whether the patent authority actually engaged with your evidence. A refusal that overlooks your experimental submissions may be vulnerable to challenge. Build your patent strategy around the science, document every comparative advantage meticulously, and never assume that the strength of your data will speak for itself without being explicitly addressed in the examiner's reasoning.